Scientifically proven benefits of mint Lesion™ in clinical routine
In contrast to clinical trials, unstructured free-text reporting is still common in the clinical routine. Such reports often lack content and clarity,…
New iRECIST whitepaper published
We are happy to present our newly published whitepaper on iRECIST and its application. This is available here on our homepage as well as on www.irecis…
New iRECIST Oncologic Response Criteria already in clinical use at the University Medical Center – Tübingen, Germany
Shortly following the release of the new iRECIST- oncologic response criteria (Lancet Oncology, March 2017) the University Medical Center in Tübingen,…
Novel oncologic therapy response criteria (iRECIST and more)
Advances in oncology therapies, such as novel immune-related agents, require adapted and refined criteria and guidelines for the assessment and…
About Cookies
This website uses cookies. Those have two functions: On the one hand they are providing basic functionality for this website. On the other hand they allow us to improve our content for you by saving and analyzing anonymized user data. You can redraw your consent to using these cookies at any time. Find more information regarding cookies on our Data Protection Declaration and regarding us on the Imprint.
